The New England Journal of Medicine, the most popular medical journal in the United States, validated, this Thursday, the full results of the clinical trials of the Covid-19 vaccine developed by the American-German alliance Pfizer-BioNTech.
The results confirm a “triumph” of the vaccine, the scientific journal said in an editorial.
The results reviewed by the U.S. Medicines Agency (FDA)
At the same time, an expert committee convened by the United States Medicines Agency (FDA) began to publicly examine the product’s data on Thursday, with the aim of recommending whether or not it was authorized for marketing. , which leaves little doubt.
The manufacturers themselves published the results in press releases on Nov. 18, and on Tuesday the FDA released its own detailed summary of the results on the vaccine’s efficacy and safety. Thursday’s publication confirms the very high efficacy: vaccinated people had a 95% lower risk of contracting Covid-19, the disease caused by the new coronavirus. And efficacy was similar regardless of age, gender, ethnicity, weight, or the presence of pathologies.
No serious security issues for the journal
The study also confirms the safety of the vaccine. Adverse effects such as pain around the injection site in the arm, fatigue and headaches are common, but no serious safety concerns were noted in the clinical trial, which has so far enrolled 44,000 people. half of whom received the vaccine and the other half a placebo.
The validation by a peer-review committee of independent scientists from Pfizer and the FDA is further confirmation of test results, and represents the highest level of scientific validation. Two managers of New England Journal of Medicine, in their editorial, highlight “minor problems” in the data, including the unknown about the vaccine’s ability to prevent asymptomatic forms of the disease. But they conclude: “Nonetheless, the results of the trial are impressive enough to hold true in any analysis. It is a triumph ”.